

Design, Synthesis, and Evaluation of Glycopeptides Containing Glucosamine

Guichao Xu¹, Xiaomin Wang², Meng Zhang¹, Li Zeng¹, Hong Li¹, Pengchao Gao¹ and Jianwei Zhang^{1*}¹College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, PRC, China²Department of Physiology, Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing 100069, PRC, China

Abstract

In this study, several novel peptidomimetics were designed and synthesized as potential anti-inflammatory agents. Their anti-inflammatory activity was evaluated using a xylene-induced ear edema model assay. Some of the compounds demonstrated inhibitory activity against xylene-induced inflammation similar to the positive control, aspirin.

Keywords: Amino sugar; Glycopeptide; Glucosamine; Inflammation

Introduction

Inflammation and various inflammatory disorders are widely prevalent all over the world. They afflict large percentage of the world's population. Inflammation is a normal protective response of mammalian tissues to a variety of hostile agents including infectious organisms, noxious chemicals, physical injury or tumor growth leading to local accumulation of plasmic fluid and blood cells. Although inflammation is a defense mechanism, the complex events and mediators involved in the inflammatory reaction can induce, maintain and aggravate many disorders. Inflammation are associated with many pathophysiology of various clinical conditions like arthritis, cancer and vascular diseases. Drugs used for the treatment of acute and chronic inflammatory disorders are usually directed at the inflammatory processes. Hence, the employment of anti-inflammatory agents may be helpful in the therapeutic treatment of those pathologies associated with inflammatory reactions. Through years of ingenious syntheses and structural modifications, which usually accompany design and development of new drug substances, many non-steroidal anti-inflammatory agents have been prepared and marketed. These have been of immense help in the management of various inflammatory conditions like rheumatism, arthritis and breast pain. However, further development of a novel class of anti-inflammatory agents is needed.

The carbohydrates of glycoproteins have been subjected to an increasing interest during the last few years because they play important roles in numerous biological processes including modification of proteins, the immune response [1-3], cell adhesion [4-7], inflammation, tumor metastasis [8], and substrate- receptor recognition [9,10]. The effects of carbohydrates on biological activity and stability of glycoproteins has been studied previously [11,12].

Carbohydrates that coat the surfaces of bacteria are capable of inducing an immune response that can recognize whole bacteria [13-16], and some functional glycoproteins that are expressed on tumour cell surfaces, have been shown to induce specific antitumour cell antibody responses in mice and patients [17]. There is a growing interest in carbohydrate mimetic peptides as vaccines to target cell surface polysaccharides of infectious bacteria and tumour [18].

Owing to the inherent complexity of carbohydrates, glycosylation can produce enormous structural diversity in proteins and induce a variety of functional changes. Since glycosyl amino acids and glycopeptides may be of value for medicinal chemistry, another important issue is their stability toward enzymatic degradation under physiological conditions. The field of glycobiology has grown explosively, and the interest in the development of methods for the synthesis of glycoconjugates is rapidly expanding as their biological and medical roles come into focus. Recent progress in this area has

been remarkable, and relatively carbohydrate moieties have been covalently attached to amino acids for incorporation into glycopeptide sequences. Thus, many efforts have been devoted to establish easy and efficient methods for glycopeptide synthesis [19,20].

The synthesis of monosaccharide conjugates is more straightforward than disaccharide or higher order oligosaccharide conjugates and this should facilitate a more rapid investigation of this possibility. We were interested to develop compounds reduced in carbohydrate character (monosaccharides). Amino sugars are widely distributed in living organisms and occur as constituents of glycoproteins, glycolipids, bacterial lipopolysaccharides, and proteoglycans. Glucosamine, an amino monosaccharide, is the most common amino sugar and is generally found as an *N*-acetylated and β -linked glycoside and is a natural component of glycoproteins found in connective tissues and gastrointestinal mucosal membranes. Glucosamine (GlcN) salts (sulfate and chloride) represent a new generation of drugs, which possess potentially chondroprotective or disease-modifying properties and were originally suggested to promote the repair of damaged cartilage. Since the first publication of Bohne in 1969 showing that GlcN can be used as a single pharmacologic agent to relieve the symptoms of osteoarthritis. Glucosamine has recently received a great deal of attention from the public as a potential treatment for OA [21]. Furthermore, the multiple antioxidant activity of glucosamine was evident as it showed pronounced reducing power, superoxide/hydroxyl-radical scavenging ability. Because it is non-toxic, it may be a desired food supplement as a potential antioxidant. Experimental evidence was presented that glucosamine possess a unique range of anti-inflammatory activities and inhibit IL-1 β - and TNF- α -induced NO production in normal human articular chondrocytes. It is also a therapeutic agent for inflammatory bowel diseases [22].

Peptides related to Arg-Gly-Asp (RGD) are known to contribute various biologic functions. Integrin receptors constitute a large family of proteins with structural characteristics of noncovalent heterodimeric glycoproteins formed of α and β subunits [23,24]. One important recognition site for many integrins is the arginine-glycine-asparagine

***Corresponding author:** Jianwei Zhang, College of Pharmaceutical Sciences, Capital Medical University, Beijing 100069, PRC, China, Tel: 86-10-8391-1522; Fax: 86-10-8391-1533; E-mail: jwzhang2006@163.com

Received May 21, 2014; Accepted June 27, 2014; Published June 29, 2014

Citation: Xu G, Wang X, Zhang M, Zeng L, Li H, et al. (2014) Design, Synthesis, and Evaluation of Glycopeptides Containing Glucosamine. Med chem 4: 494-500. doi:[10.4172/2161-0444.1000184](http://dx.doi.org/10.4172/2161-0444.1000184)

Copyright: © 2014 Xu G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

tripeptide sequence. Regarding RGD-dependent integrins, $\alpha_v\beta_3$ and $\alpha_v\beta_5$ receptors have received increasing attention as therapeutic targets, as the integrins $\alpha_v\beta_3$ and $\alpha_v\beta_5$ can be expressed by both tumor cells and tumor endothelial cells [25-27]. It is speculated that drugs that inhibit the adhesive function of these integrins can inhibit tumor growth. Among selective receptor-targeting small peptides, integrin-mediated RGD peptide appear attractive candidates. Moreover, it is well known that RGD peptide can suppress platelet aggregation by blocking the interaction between platelet and fibrinogen.

There is an increased interest in the use of hybrid molecules for drug discovery against a multitude of disease indications [28-32]. A twin drug bearing two different pharmacophoric entities is expected to bind to the respective receptors for each monomeric ligand and could elicit the corresponding effects derived from the individual receptors [33]. Furthermore, a twin drug can sometimes show an unexpected effect, which may not be predicted from each monomeric unit. The present work is towards the development and identification of new molecules as high potent anti-inflammatory agents.

Amide bond is very stable in buffer solution at pH 7.4 and in culture medium. Amides are an important functional group widely found in natural products, pharmaceuticals, and polymers. They may be prepared by coupling reactions between carboxylic acids and amines [34-36]. The synthetic design used for preparation of glycosyl amides was based upon a number of reasons: (1) glucosamine possess the biological activity; (2) *N*-acetylglucosamine has several potential advantages over glucosamine as a potential therapeutic anti-inflammatory agent. In addition, it has been reported that some orally administered peptide analogues could be effectively absorbed through the intestinal peptide transport system. Amino acids are attractive because they possess structurally diverse side chains which allow to manipulate of the pharmacokinetics profiles of the compounds by using different amino acids. In this context, an interest has been increased in linking glucosamine with RGD peptide by the addition different lipophilic amino acid residues. Different lipophilic amino acids were used as building units for the preparation of a series tetrapeptide RGDAA (AA=amino acid residues) as building blocks: these were RGD peptide derivatives C-linked via valine, phenylalanine and serine. In this study, the synthesis of peptidomimetics in which RGDAA were conjugated via an amide linkage to a monosaccharide (glucosamine) with variations in the peptide part were reported [32]. Glucosamine and *N*-acetylglucosamine have been reported to possess interesting biological activity [33-37], therefore the creation of these compounds would be useful for further biological evaluation, as well as for detailed structure-activity studies and may have potential as drugs or as leads for drug development.

Materials and Methods

General procedures

Unless otherwise stated, all reactions were under a nitrogen atmosphere (1 bar). The agents used in this work were purchased from Sigma Chemical Co (USA). Optical rotations were determined with a Schmidt+Haensch Polartromic D instrument (Germany). IR spectra were recorded with an Avatar 330, Nicolet, USA spectrometer. ^1H and ^{13}C NMR spectra were recorded at 300 MHz on a VXR-300 instrument or at 500 MHz on a Bruker Am-500 instrument in DMSO-*d*₆ with tetramethylsilane as internal standard and chemical shifts are expressed in ppm (δ). Chromatography was performed on Qingdao silica gel H (Qingdao of China). TLC analysis was carried out on silica gel F₂₅₄. The purities (> 95%) of the intermediates and the products were confirmed by TLC (Merck silica gel plates of type 60 F₂₅₄, 0.25 mm layer thickness,

Germany) and HPLC (Waters, C₈ column 4.6×250 mm, Ireland). MS was acquired on a Quattro Micro ZQ2000, Waters, USA instrument, *m/z* values are reported. High-resolution mass spectra were recorded with microTOF-Q mass spectrometer.

Syntheses

***N*-(Val-Asp(MeO)-Gly-Arg(NO₂)-Boc)-2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucoamine:** HOBt (800 mg, 5.93 mmol) and DCC (1.20 g, 5.83 mmol) were added to a solution of Boc-Arg(NO₂)-Gly-Asp(OMe)-Val-OH (3.48g, 5.76 mmol) in anhydrous THF (30 mL) at 0°C. The reaction mixture was stirred at 0°C for 30 min. The solution of 2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucoamine (2.95 g, 5.47 mmol) in anhydrous THF (20 mL) was added and adjusted to pH 9 with *N*-methylmorpholine. The reaction mixture obtained was kept at 0°C for 2 h followed by at room temperature for 24 h. DCU formed was removed by filtration. The filtrate was evaporated under reduced pressure and the residue was dissolved in EtOAc (50 mL). The solution was washed successively with saturated NaHCO₃, 5% KHSO₄ and saturated NaCl and the organic phase was separated and dried over Na₂SO₄. Following filtration and evaporation under reduced pressure, the residue was purified by column chromatography (20:1 CH₂Cl₂-MeOH) to provide Compound **9a** (4.23 g, 3.76 mmol, 69%, $\alpha : \beta = 1.8:1$). ^1H NMR (500 MHz, DMSO-*d*₆): δ 8.48 (1H, brs, N-H), 8.35 (1H, d, *J* = 8.5 Hz, N-H), 8.29 (1H, d, *J* = 9.0 Hz, N-H), 8.24 (1H, d, *J* = 8.0 Hz, N-H), 8.19 (1H, d, *J* = 9.0 Hz, N-H), 8.15 (1H, m, N-H), 7.77 (1H, d, *J* = 9.0 Hz, N-H), 7.66 (1H, d, *J* = 9.0 Hz, N-H), 7.44-7.15 (19H, m, Ar-H), 6.94 (1H, t, *J* = 6.9 Hz, Ar-H), 4.78 (1H, m, CH), 4.77 (1H, d, *J* = 4.0 Hz, H-1 α), 4.76 (1H, d, *J* = 8.5 Hz, H-1 β), 4.70 (4H, m, CH₂Ph), 4.66 (4H, m, CH₂Ph), 4.37 (1H, d, *J*₁ = 9.0 Hz, *J*₂ = 6.0 Hz, CH), 4.31 (1H, dd, *J*₁ = 9.0 Hz, *J*₂ = 6.0 Hz, CH), 3.94 (2H, dd, *J*₁ = 8.5 Hz, *J*₂ = 3.5 Hz, CH₂), 3.83-3.64 (6H, m, CH H-2, H-3, H-4, H-5, H-6a), 3.59 (3H, s, CH₃), 3.57 (1H, m, H-6b), 2.73 (1H, m, CH), 2.54 (1H, m, CH), 2.08 (1H, m, CH), 1.65 (1H, m, CH₂), 1.51 (3H, m, CH₂), 1.38 (9H, s, CH₃), 0.84 (3H, d, *J* = 6.5 Hz, CH₃), 0.77 (3H, d, *J* = 6.5 Hz, CH₃), 0.76 (3H, d, *J* = 6.5 Hz, CH₃), 0.70 (3H, d, *J* = 6.5 Hz, CH₃); ^{13}C NMR(125MHz, CDCl₃) δ 172.7, 171.4, 171.2, 171.0, 170.9, 170.3, 170.2, 169.4, 169.1, 159.8, 155.9, 139.1, 139.0, 138.7, 138.6, 138.5, 137.9, 137.7, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 96.7, 79.9, 79.4, 79.9, 78.7, 74.7, 74.6, 74.3, 72.8, 70.9, 69.1, 69.0, 58.1, 57.8, 54.4, 53.5, 52.0, 51.9, 49.8, 42.6, 42.4, 37.1, 36.2, 31.4, 31.2, 29.6, 28.7, 25.2, 19.8, 19.6, 18.3, 17.9; IR (cm⁻¹, KBr, neat): 3286, 1643, 741; ESIMS *m/z* 1148(M+Na); HRMS calcd for : (C₅₇H₇₆N₉O₁₅ + 1), *m/z* (1126.5455); found, *m/z* (1126.5366).

***N*-(Phe-Asp(OMe)-Gly-Arg(NO₂)-Boc)-2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy- α -D-glucosamine:** HOBt (310 mg, 2.29 mmol) and DCC (500 mg, 2.43 mmol) were added to a solution of Boc-Arg(NO₂)-Gly-Asp(OMe)-Phe-OH (1.46 g, 2.24 mmol) in anhydrous THF (10 mL) at 0°C. The reaction mixture was stirred at 0°C for 30 min. The solution of 2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucoamine (1.22 g, 2.26mmol) in anhydrous THF (20 mL) was added and adjusted to pH 9 with *N*-methylmorpholine. The reaction mixture obtained was kept at 0°C for 2 h followed by at room temperature for 24 h. DCU formed was removed by filtration. The filtrate was evaporated under reduced pressure and the residue was dissolved in EtOAc (50 mL). The solution was washed successively with saturated NaHCO₃, 5% KHSO₄ and saturated NaCl and the organic phase was separated and dried over Na₂SO₄. Following filtration and evaporation under reduced pressure, the residue was purified by column chromatography (20:1 CH₂Cl₂-MeOH) to provide Compound **9b** (1.8 g, 1.53 mmol, 79%). [α]_D²⁵ = +21.5 (C = 0.7, MeOH); IR (cm⁻¹, KBr, neat): 3287, 1636; ^1H NMR (500 MHz, DMSO-*d*₆): δ 8.33 (1H, d, *J* = 8.4 Hz, N-H), 8.03 (1H, d, *J* = 8.4 Hz, N-H), 7.94 (1H, d, *J* = 8.4 Hz, N-H), 7.41-7.14 (25H, m, Ar-H), 4.79 (1H, d, *J* = 3.0 Hz, H-1), 4.78-4.69 (7H, m, CH₂Ph, CH), 4.63 (1H, m,

CH), 4.56 (2H, m, CH₂Ph), 3.99 (2H, m, CH, H-2), 3.85 (1H, t, J = 9.5 Hz, H-3), 3.79 (1H, m, H-5), 3.68 (4H, m, CH₂, H-6a, H-6b), 3.58 (1H, t, J = 9.5 Hz, H-4), 3.52 (3H, s, CH₃), 3.13 (2H, m, CH₂), 2.94 (1H, dd, J₁ = 13.2 Hz, J₂ = 3.3 Hz, CH₂), 2.76 (1H, dd, J₁ = 13.2 Hz, J₂ = 3.0 Hz, CH₂), 2.64 (1H, dd, J₁ = 16.2 Hz, J₂ = 6.0 Hz, CH₂), 2.44 (1H, dd, J₁ = 16.2 Hz, J₂ = 7.8 Hz, CH₂), 1.66 (1H, m, CH₂), 1.52 (3H, m, CH₂), 1.38 (9H, s, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 172.8, 171.4, 171.0, 170.2, 169.1, 159.6, 155.9, 139.1, 139.0, 138.7, 138.6, 138.0, 137.9, 129.6, 128.8, 128.7, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 126.7, 96.7, 79.8, 78.9, 78.8, 74.6, 74.4, 72.8, 71.0, 69.1, 54.4, 54.3, 53.5, 51.9, 49.5, 42.3, 38.0, 36.2, 29.5, 28.6, 25.2; ESIMS *m/z* 1196(M+Na); HRMS calcd for: (C₆₁H₇₆N₉O₁₅+1), *m/z* (1174.5455); found, *m/z* (1174.5705).

***N*-(Ser(OBn)-Asp(OMe)-Gly-Arg(NO₂)-Boc)-2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-α-D-glu-cosamine:** HOBt (135 mg, 1.00 mmol) and DCC (200 mg, 0.97 mmol) were added to a solution of Boc-Arg(NO₂)-Gly-Asp(OMe)-Ser(OBn)-OH (560 mg, 0.82 mmol) in anhydrous THF (15 mL) at 0°C. The reaction mixture was stirred at 0°C for 30 min. The solution of 2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucoamine (493 mg, 0.91 mmol) in anhydrous THF (5 mL) was added and adjusted to pH 9 with *N*-methylmorpholine. The reaction mixture obtained was kept at 0°C for 2 h followed by at room temperature for 24 h. DCU formed was removed by filtration. The filtrate was evaporated under reduced pressure and the residue was dissolved in EtOAc (50 mL). The solution was washed successively with saturated NaHCO₃, 5% KHSO₄ and saturated NaCl and the organic phase was separated and dried over Na₂SO₄. Following filtration and evaporation under reduced pressure, the residue was purified by column chromatography (20:1 CH₂Cl₂-MeOH) to provide Compound 9c (600 mg, 0.50 mmol, 61%). [α]_D²⁵ = +28.2 (C = 1.0, MeOH); IR (cm⁻¹, KBr, neat): 3287, 1651; ¹HNMR (500 MHz, DMSO-*d*₆): δ 8.23 (1H, d, J = 8.7 Hz, N-H), 8.10 (1H, d, J = 8.1 Hz, N-H), 7.39-7.14 (25H, m, Ar-H), 4.77 (1H, d, J = 3.5 Hz, H-1), 4.76 (1H, m, CH), 4.72 (5H, m, CH₂Ph, CH₂), 4.52 (4H, m, CH₂Ph), 4.37 (2H, m, CH₂Ph), 3.96 (2H, m, CH, H-2), 3.82 (1H, t, J = 8.7 Hz, H-3), 3.78 (1H, m, H-5), 3.72 (2H, m, H-6a, H-6b), 3.66 (2H, m, CH₂), 3.59 (3H, m, H-4, CH₂), 3.54 (3H, s, CH₃), 3.12 (2H, m, CH₂), 2.74 (1H, dd, J₁ = 16.2 Hz, J₂ = 6.0 Hz, CH₂), 2.57 (1H, dd, J₁ = 16.2 Hz, J₂ = 6.0 Hz, CH₂), 1.65 (1H, m, CH₂), 1.51 (3H, m, CH₂), 1.38 (9H, s, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 172.7, 171.0, 170.5, 169.7, 169.2, 159.6, 155.9, 139.1, 138.7, 138.6, 138.5, 137.9, 128.7, 128.6, 128.5, 128.3, 128.2, 128.1, 127.9, 127.8, 127.7, 96.7, 79.8, 78.8, 78.6, 74.6, 74.3, 72.8, 72.5, 71.0, 70.3, 69.1, 66.5, 55.5, 54.3, 53.5, 53.4, 51.9, 49.6, 42.4, 36.5, 29.5, 28.6, 25.1; ESIMS *m/z* 1204 (M+1); HRMS calcd for: (C₆₂H₇₈N₉O₁₆+1), *m/z* (1204.5561); found, *m/z* (1204.5747).

***N*-(Val-Asp-Gly-Arg(NO₂)-Boc)-2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-α-D-glucosamine:** The solution of 9a (1.50 g, 1.33 mmol) in 2M NaOH (4 mL) in methanol (20 mL) and dioxane (60 mL) was stirred at 0°C until all the starting material was consumed as indicated by TLC (24 hr). The reaction mixture was neutralized (pH 7) with KHSO₄ and evaporated to remove the solvent. The residue was added water at 0°C (50 mL) and KHSO₄ to pH 2. Following filtration, the residue was purified by column chromatography (15:1 CH₂Cl₂-MeOH) to provide Compound 10a α-anomer (300 mg, 0.270 mmol, 74%) and 10a β-anomer (1.1g, 0.990 mmol, 20%). 10a α-anomer: [α]_D²⁵ = +88.6 (C = 0.2, MeOH); ¹HNMR (500 MHz, DMSO-*d*₆): δ 7.40-7.15 (20H, m, Ar-H), 4.77 (1H, m, CH), 4.76 (1H, d, J = 3.5 Hz, H-1), 4.68 (4H, m, CH₂Ph), 4.53 (4H, m, CH₂Ph), 4.32 (1H, m, CH), 3.95 (2H, m, CH₂), 3.83 (1H, m, CH), 3.80 (2H, m, H-2, H-3), 3.67 (3H, m, H-4, H-6a, H-6b), 3.56 (1H, q, J = 9.0 Hz, H-5), 3.13 (2H, m, CH₂), 2.67 (1H, m, CH₂), 2.56 (1H, m, CH₂), 1.98 (1H, m, CH), 1.66 (1H, m, CH₂), 1.51 (3H, m, CH₂), 1.38 (9H, s, CH₃), 0.80 (6H, m, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 172.7, 171.4, 170.6, 169.3, 168.9, 159.6,

155.9, 139.1, 139.0, 138.7, 138.6, 137.9, 128.8, 128.7, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 127.8, 96.7, 79.8, 79.4, 78.9, 78.7, 74.6, 74.4, 72.8, 70.9, 69.1, 57.9, 54.3, 53.5, 49.9, 42.3, 37.2, 36.2, 31.1, 29.6, 28.7, 25.0, 19.8, 19.7, 18.3, 17.8; IR (cm⁻¹, KBr, neat): 3287, 1643, 741; ESIMS *m/z* 1111(M); HRMS calcd for: (C₅₆H₇₂N₉O₁₅), *m/z* (1110.515336); found, *m/z* (1110.5226). 10a β-anomer: [α]_D²⁵ = +51.4 (C = 0.1, MeOH); IR (cm⁻¹, KBr, neat): 3287, 1643, 741; ¹HNMR (500 MHz, DMSO-*d*₆): δ 7.39-7.16 (20H, m, Ar-H), 4.79 (1H, d, J = 11.4 Hz, H-1), 4.76 (1H, m, CH), 4.69 (3H, m, CH₂Ph), 4.55 (5H, m, CH₂Ph), 4.50 (1H, m, CH), 4.32 (1H, m, CH), 3.95 (2H, m, CH₂), 3.77 (3H, m, CH, H-2, H-3), 3.67 (3H, m, H-4, H-6a, H-6b), 3.55 (1H, m, H-5), 3.14 (2H, m, CH₂), 2.59 (2H, m, CH₂), 1.92 (1H, m, CH), 1.68 (1H, m, CH₂), 1.51 (3H, m, CH₂), 1.38 (9H, s, CH₃), 0.77 (3H, d, J = 6.5 Hz, CH₃), 0.71 (3H, d, J = 6.5 Hz, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 173.9, 172.5, 171.9, 170.6, 169.7, 168.5, 159.6, 155.8, 139.2, 138.7, 138.6, 137.9, 137.8, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 96.6, 79.3, 79.0, 78.6, 74.6, 74.3, 72.8, 70.9, 69.1, 68.9, 57.9, 54.3, 53.5, 42.3, 40.8, 38.6, 31.3, 29.7, 28.7, 25.4, 19.8, 19.6, 18.5, 18.0, 17.9; ESIMS *m/z* 1111(M); HRMS calcd for: (C₅₆H₇₂N₉O₁₅-1), *m/z* (1110.5153); found, *m/z* (1110.5176).

***N*-(Phe-Asp-Gly-Arg(NO₂)-Boc)-2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-α-D-glucosamine:** The solution of 9b (1.38g, 1.17mmol) in 2M NaOH (2 mL) in methanol (10 mL) and dioxane (30 mL) was stirred at 0°C until all the starting material was consumed as indicated by TLC (24 hr). The reaction mixture was neutralized (pH 7) with KHSO₄ and evaporated to remove the solvent. The residue was added water at 0°C (50 mL) and KHSO₄ to pH 2. Following filtration, the residue was purified by column chromatography (15:1 CH₂Cl₂-MeOH) to provide Compound 10b (0.950 g, 0.820 mmol, 70%). [α]_D²⁵ = +49.2 (C = 0.2, MeOH); IR (cm⁻¹, KBr, neat): 3294, 1643, 741; ¹HNMR (300 MHz, DMSO-*d*₆): δ 8.49 (1H, brs, N-H), 8.22 (1H, d, J = 6.1Hz, N-H), 7.99 (1H, brs, N-H), 7.40-7.18 (25H, m, Ar-H), 6.93 (1H, d, J = 7.5Hz, N-H), 4.78 (2H, m, CH), 4.72 (1H, d, J = 3.3Hz, H-1), 4.70 (2H, m, CH₂Ph), 4.54 (6H, m, CH₂Ph), 3.88 (4H, m, CH, H-2, H-3, H-5), 3.62 (5H, m, CH₂, H-4, H-6a, H-6b), 3.13 (2H, m, CH₂), 2.94 (1H, m, CH), 2.68 (2H, t, J = 12.0 Hz, CH), 2.39 (1H, m, CH), 1.70 (1H, m, CH₂), 1.51 (3H, m, CH₂), 1.37 (9H, s, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 172.5, 172.1, 172.0, 169.7, 168.6, 159.6, 155.8, 139.2, 139.1, 138.7, 138.6, 138.5, 138.2, 137.9, 129.5, 129.4, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 126.6, 96.8, 79.7, 78.9, 78.7, 74.6, 74.4, 72.8, 71.0, 69.1, 54.4, 53.6, 53.5, 49.6, 42.1, 38.1, 29.8, 28.7, 25.2; ESIMS *m/z* 1158(M-1); HRMS calcd for: (C₆₀H₇₂N₉O₁₅-1), *m/z* (1158.5153); found, *m/z* (1158.5303).

***N*-(Ser-Asp-Gly-Arg(NO₂)-Boc)-2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-α-D-glucosamine:** The solution of 9c (200 mg, 0.166 mmol) in 2 M NaOH (0.8 mL) in methanol (50 mL) and dioxane (15 mL) was stirred at 0°C until all the starting material was consumed as indicated by TLC (24 hr). The reaction mixture was neutralized (pH 7) with KHSO₄ and evaporated to remove the solvent. The residue was added water at 0°C (50 mL) and KHSO₄ to pH 2. Following filtration, the residue was purified by column chromatography (15:1 CH₂Cl₂-MeOH) to provide Compound 10c (147 mg, 0.123 mmol, 75%). [α]_D²⁵ = +24.4 (C = 0.2, MeOH); IR (cm⁻¹, KBr, neat): 3302, 1651; ¹HNMR (500 MHz, DMSO-*d*₆): δ 8.46 (1H, d, J = 8.0 Hz, N-H), 8.26 (1H, d, J = 6.5 Hz, N-H), 7.39-7.14 (25H, m, Ar-H), 4.78 (2H, m, H-1, CH), 4.68 (4H, m, CH₂Ph), 4.50 (5H, m, CH, CH₂Ph), 4.35 (2H, m, CH₂Ph), 3.98 (2H, m, CH, H-2), 3.80 (3H, m, H-3, CH₂), 3.64 (3H, m, H-5, H-6a, H-6b), 3.53 (3H, m, H-4, CH₂), 3.15 (2H, m, CH₂), 3.02 (1H, m, CH₂), 2.65 (1H, m, CH₂), 1.69 (1H, m, CH₂), 1.52 (3H, m, CH₂), 1.38 (9H, s, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 172.6, 170.2, 168.5, 159.6, 155.8, 139.2, 138.7, 138.6, 138.5, 137.9, 137.8, 128.8, 128.5, 128.4, 128.3,

128.2, 128.1, 127.9, 79.7, 78.7, 78.6, 74.6, 74.4, 72.8, 72.5, 70.9, 70.5, 69.1, 68.9, 54.3, 53.6, 51.9, 49.6, 42.2, 36.5, 29.6, 28.7, 25.2; ESIMS m/z 1189(M); HRMS calcd for: (C₆₁H₇₄N₉O₁₆-1), m/z (1188.5259); found, m/z (1188.5345).

N-(Val-Asp-Gly-Arg)-2-amino-2-deoxy- α -D-glucosamine: The solution of **10a** (30 mg, 0.0270 mmol) in TFA (2.1 mL) and CF₃SO₃H (0.7 mL) was stirred at 0°C until all the starting material was consumed as indicated by TLC (3 hr). The reaction mixture was added Et₂O (80 mL), the precipitate was collected by filtration that was added NH₃·H₂O to pH=9. Subsequently, The residue was added HAc to pH=4 and purified by column chromatography (Sephadex G-10) to provide Compound **11a** (6.2 mg, 0.008 mmol, 38%). IR (cm⁻¹, KBr, neat): 3132, 1678; ¹HNMR (500 MHz, DMSO-*d*₆): δ 4.21-3.81 (7H, m, CH), 3.81-3.42 (5H, m, CH), 3.04 (2H, m, CH₂), 2.21 (2H, m, CH₂), 1.90 (1H, m, CH), 1.52 (4H, m, CH₂), 0.84 (6H, d, J = 6.0 Hz, CH₃), 3.53 (3H, m, H-4, CH₂), 3.15 (2H, m, CH₂), 3.02 (1H, m, CH₂), 2.65 (1H, m, CH₂), 1.69 (1H, m, CH₂), 1.52 (3H, m, CH₂), 1.38 (9H, s, CH₃); ¹³CNMR(125MHz, CDCl₃) δ 172.6, 170.2, 168.5, 159.6, 155.8, 139.2, 138.7, 138.6, 138.5, 137.9, 137.8, 128.8, 128.5, 128.4, 128.3, 128.2, 128.1, 127.9, 79.7, 78.7, 78.6, 74.6, 74.4, 72.8, 72.5, 70.9, 70.5, 69.1, 68.9, 54.3, 53.6, 51.9, 49.6, 42.2, 36.5, 29.6, 28.7, 25.2; ESIMS m/z 607(M+1); HRMS calcd for: (C₂₃H₄₃N₈O₁₁+1), m/z (607.3046); found, m/z (607.3358).

N-(Phe-Asp-Gly-Arg)-2-amino-2-deoxy- α -D-glucosamine: The solution of **10b** (30 mg, 0.026 mmol) in TFA (2.1 mL) and CF₃SO₃H (0.7 mL) was stirred at 0°C until all the starting material was consumed as indicated by TLC (3 hr). The reaction mixture was added Et₂O (80 mL), the precipitate was collected by filtration that was added NH₃·H₂O to pH=9. Subsequently, the residue was added HAc to pH=4 and purified by column chromatography (Sephadex G-10) to provide Compound **11b** (7.3 mg, 0.011 mmol, 43%). IR (cm⁻¹, KBr, neat): 3147, 1670; ¹HNMR (500 MHz, DMSO-*d*₆): δ 4.69 (1H, d, J = 5.5 Hz, H-1), 4.66 (1H, m, CH), 4.52 (1H, m, CH), 4.37 (1H, m, CH), 4.14 (2H, m, CH), 3.71 (4H, m, CH), 3.36 (2H, m, CH), 3.17 (1H, m, CH₂), 3.08 (2H, m, CH₂), 2.77 (1H, m, CH₂), 2.31 (1H, m, CH₂), 2.29 (1H, m, CH₂), 1.83 (1H, m, CH₂), 1.55 (3H, m, CH₂); ¹³CNMR(125MHz, CDCl₃) δ 176.1, 174.1, 173.9, 171.4, 160.7, 122.4, 122.4, 121.1, 119.8, 118.8, 116.4, 114.0, 90.1, 84.3, 81.1, 74.6, 63.6, 63.0, 54.3, 54.2, 45.1, 42.5, 35.3, 32.3, 30.7, 24.8, 22.9; ESIMS m/z 653(M-1); HRMS calcd for: (C₂₇H₄₅N₈O₁₁+1), m/z (655.3046); found, m/z (655.3363).

N-(Ser-Asp-Gly-Arg)-2-amino-2-deoxy- α -D-glucosamine: The solution of **10c** (30 mg, 0.025 mmol) in TFA (2.1 mL) and CF₃SO₃H (0.7 mL) was stirred at 0°C until all the starting material was consumed as indicated by TLC (3 hr). The reaction mixture was added Et₂O (80 mL), the precipitate was collected by filtration that was added NH₃·H₂O to pH=9. Subsequently, The residue was added HAc to pH=4 and purified by column chromatography (Sephadex G-10) to provide Compound **11c** (6.5 mg, 0.011 mmol, 44%). IR (cm⁻¹, KBr, neat): 3194, 1701; ¹HNMR (300 MHz, DMSO-*d*₆): δ 7.31 (1H, brs, N-H), 4.57 (1H, m,


CH), 4.43 (1H, m, CH), 4.31 (3H, m, H-1, H-2, H-3), 4.08 (3H, m, CH, H-4, H-5), 3.66 (6H, m, H-6a, H-6b, CH₂), 3.11(2H, m, CH₂), 2.60 (2H, m, CH₂), 1.79 (2H, m, CH₂), 1.58 (2H, m, CH₂); ¹³CNMR(125MHz, CDCl₃) δ 176.1, 174.1, 173.9, 171.4, 160.7, 122.8, 122.4, 121.1, 119.8, 118.8, 116.4, 114.0, 90.1, 84.3, 81.1, 74.6, 63.6, 63.0, 54.3, 54.2, 45.1, 42.5, 35.3, 32.3, 30.7, 24.8, 22.9; ESIMS m/z 595(M+1); HRMS calcd for: (C₂₁H₃₉N₈O₁₂+1), m/z (595.2682); found, m/z (595.2987).

Results and Discussion


Chemistry

As shown in Scheme 1, Boc-Arg(NO₂)-OH and glycine benzylester (NH₂-Gly-OBzl) were reacted using the standard peptide coupling method (dicyclohexylcarbodiimide (DDC), N-hydroxybenzotriazole (HOBT) and N-methylmorpholine (NMM)) in solution followed by purification by silica gel column chromatography to afford dipeptide Boc-Arg(NO₂)-Gly-OBzl. Subsequently, removal of the benzyl group with NaOH resulted in Boc-Arg(NO₂)-Gly-OH (Compound 1) which was used to synthesize various tetrapeptides. The coupling reaction of L-Boc-Asp(OMe)-OH with different lipophilic amino acids benzylester, Val, Phe and Ser, yielded dipeptide Boc-Asp(OMe)-AA-OBzl. Subsequently, removal of the Boc group with hydrogen chloride in ethyl acetate led to N-terminal free intermediates (Compound 2a-c) which was reacted with Compound 1 using the standard peptide coupling method (DDC, HOBT, and N-methylmorpholine) to give tetrapeptides (Compound 3a-c). Removal of the benzyl group from Compound 3a-c was carried out by palladium catalyzed hydrogenolysis to give the corresponding C-terminal free compound, (Compound 4a-c), in almost quantitative yield.


The preparation of 2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucopyranoside (Compound 8) [38] using glucosamine (GlcN) salt (chloride) as starting materials is presented in Scheme 2. Initially, acylation of (GlcN) salt with (Boc)₂O resulted in N-Boc-glucosamine (Compound 6). N-Boc-glucosamine was benzylated with NaH and BnBr to give 1,3,4,6-tetra-O-benzyl-2- (tert-butylloxycarbonylamino)-2-deoxy-D-glucopyranoside (Compound 7). Subsequently, removal of the Boc group with trifluoroacetic acid in dichloromethane led to 2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucopyranoside (Compound 8) as mixture of anomers which was used for the facile preparation of mimetic peptides. The synthetic routes for the preparation of mimetic peptides from Compound 8 were presented in Schemes 3. Furthermore, Compound 8 and protected tetrapeptides Boc-Arg(NO₂)-Gly-Asp(OMe)-AA-OH (RGDAA, AA = amino acid residues) with various amino acid residues moiety as building blocks were explored to synthesize various glycosylated mimetic peptides by standard peptide coupling methods (DDC, HOBT and N-methylmorpholine) in solution phase. The products obtained were purified by silica gel column chromatography to afford 9a-c in 69%, 79% and 61% yield,



Scheme 1: Synthesis of tetrapeptides. Reagents and conditions: (i)NMM, DDC, HOBT; (ii) H₂, Pd/C.



Scheme 2: Synthesis of 2-amino-1,3,4,6-tetra-O-benzyl-2-deoxy-D-glucosamine. Reagents and conditions: (i) Boc_2O and triethylamine; (ii) BnBr , NaH , DMF (iii) CF_3COOH .



Scheme 3: Synthesis of mimetic Peptides containing glucosamine. Reagents and conditions: (i) NMM , DCC , HOBT , $\text{HO-AA-Asp(OMe)-Gly-Arg(NO}_2\text{)-Boc}$; (ii) NaOH ; (iii) CF_3COOH , $\text{CF}_3\text{SO}_3\text{H}$.

respectively. The assignment of the configuration was performed by ^1H NMR spectroscopy. The ^1H NMR spectra of 9a showed signals for the anomeric protons as doublets with coupling constants of 4.0 Hz and 8.5 Hz as a mixture of anomers ($\alpha:\beta=1.8:1$). ^1H NMR spectra of 9b-c showed signals for the anomeric protons as doublets with coupling constants of 3.0 Hz and 3.5 Hz as single anomers, which can be attributed to the anomeric effect. Subsequently, removal of the Me group with NaOH led to a set of carboxylic acid 10a-c in 94%, 70% and 75% yield, respectively. ^1H NMR spectra indicated that 10a was as a mixture of anomers which were separated by silica gel column chromatography to afford α -anomer and β -anomer in 74% and 20% yield, respectively ($\alpha:\beta=3.7:1$) and 10b-c were α -anomers. Problems were encountered at the removal of Boc group of 10a-c where using hydrogen chloride in ethyl acetate is failed. Unfortunately, the attempt to remove nitro and benzyl groups by palladium catalyzed hydrogenolysis resulted in only an intractable mixture of several products. Finally, Compound 11a-c presented were obtained following the removal of the Boc group, benzyl groups and nitro group with trifluoromethanesulfonic acid in trifluoroacetic acid as a mixture of antiomers in 38%, 43% and 44% yield respectively. The structures of glycopeptides are shown in Table 1.

Evaluation of anti-inflammatory activity

xylene-induced mouse ear edema are the typical animal models used to evaluate potential anti-inflammatory agents. They have a good reputation for screening anti-inflammatory agents. Compounds 5, 9a-c, 10a-c, 11a-c were screened for their anti-inflammatory activity by using a xylene-induced ear edema model assay [39]. The animal protocol was approved by the Committee on Animal Care and Usage (Capital Medical University). Male ICR mice (body weight, 18-20 g) were used. The animals were maintained on a 12/12 h light/dark cycle at constant temperature and humidity, and provided with free access to food and water in the home cage. They were allowed to acclimate to their new surroundings for 1 day before experiment. Mice were divided into eight groups of twelve. Mice administered orally with 0.5% CMC were used as the negative control group, and mice administered orally with Aspirin (at a dosage of 100 mg/kg) in CMC were used as positive control. The compounds to be tested were prepared as fine homogenized suspensions in 0.5% CMC at the concentration of 1 mM and were administered orally to the animals at a dosage of 10 $\mu\text{mol/kg}$ body weight 30 min before xylene was applied to both the anterior and posterior surfaces of the right ear. The left ear was considered as control. Two hours after xylene treatment, all mice were decapitated











No	Chemical structure	No	Chemical structure
9a	 Boc-(O ₂ N)Arg-Gly-(MeO)Asp-Val-NH	9b	 Boc-(O ₂ N)Arg-Gly-(MeO)Asp-Phe-NH
9c	 Boc-(O ₂ N)Arg-Gly-(MeO)Asp-(BnO)Ser-NH	10a(α)	 Boc-(O ₂ N)Arg-Gly-Asp-Val-NH
10a(β)	 Boc-(O ₂ N)Arg-Gly-Asp-Val-NH	10b	 Boc-(O ₂ N)Arg-Gly-Asp-Phe-NH
10c	 Boc-(O ₂ N)Arg-Gly-Asp-Ser-NH	11a	 H ₂ N-Arg-Gly-Asp-Val-NH
11b	 H ₂ N-Arg-Gly-Asp-Phe-NH	11c	 H ₂ N-Arg-Gly-Asp-Ser-NH

Table 1: Structures of glucosamine mimetic peptides derivatives.

Compound ^a	Edema weight (X ± SD mg)	Inhibition ratio (%)
CMC	7.6 ± 2.8	31.8 ± 23.9
Aspirin	0.9 ± 0.6	89.5 ± 7.0 ^c
5	3.5 ± 2.2	64.3 ± 23.0 ^b
9a	1.2 ± 1.1	87.5 ± 11.8 ^c
9b	2.6 ± 1.6	78.5 ± 13.1 ^b
9c	1.7 ± 1.1	86.8 ± 9.0 ^c
10a-α	1.9 ± 1.5	84.5 ± 12.1 ^b
10a-β	2.0 ± 1.4	81.1 ± 15.7 ^b
10b	1.6 ± 1.3	86.7 ± 10.5 ^c
10c	1.2 ± 0.9	90.7 ± 7.1 ^c
11a	2.4 ± 1.4	82.6 ± 11.0 ^b
11b	1.9 ± 1.3	85.7 ± 9.9 ^c
11c	1.7 ± 0.8	86.9 ± 6.3 ^c

^aAspirin=Positive control, CMC=Vehicle, Dose of mimetic peptides derivatives=10 μmol/kg, dose of aspirin = 100 mg/kg; n = 12.

^bCompared to CMC p<0.01.

^cCompared to CMC p<0.01, Compared to 5 p<0.05.

Table 2: Anti-inflammatory activities of glucosamine mimetic peptides derivatives determined using an xylene-induced ear edema model.

by diethyl ether anesthesia and both ears were removed and weighed. The increase in weight caused by xylene was measured through subtracting the weight of the untreated left ear section from that of the treated right ear section. The inhibition ratio (%) in describing the anti-inflammatory effects was determined:

$$\text{Inhibition ratio \%} = (1 - A/B) \times 100\%$$

A: The increase in weight caused by xylene

B: The weight of the untreated left ear section

The efficacies of these derivatives anti-inflammatory activity were compared with the positive control and the negative control, respectively. The percentage of inhibition is used as an indication of anti-inflammatory activity. The anti-inflammatory activity of these derivatives is summarized in Table 2. The results revealed that all the derivatives tested significantly reduced ear edema and exhibited a significant inhibitory activity against xylene-induced inflammation

in mice in comparison with the negative control group. The tested derivatives showed inhibition ratio ranging from 78.5% to 90.7% (P <0.01) with Compound 10c being most effective. The ear edema inhibition ratio for Compound 10c at 10 μmol/kg was calculated to be 90.7%, while that was 89.5% for aspirin at the dosage of 100 mg/kg. Inhibition ratio of compound 10c was clearly better than that produced by aspirin. To understand the contribution of the tetrapeptides (RGDAA) containing RGD in glucosamine mimetic peptides to the anti-inflammatory activities, glucosamine 5 was used as reference compounds. Comparison of inhibition ratio values of tested derivatives and glucosamine (64.3%) showed that the presence of tetrapeptides can increase the activity, suggesting that the tetrapeptides structure had a definite contribution to the activity. Further investigation is required on the biological activity of these compounds in order to rationalize these observations. This study provided useful information for the further design of novel potent agents.

Conclusions

In summary, a novel class of glucosamine mimetic peptides containing bioactive RGD peptides derivatives were designed, synthesized and evaluated for their anti-inflammatory effect. It was found that Compounds 10c exhibited the most potent anti-inflammatory activity. The tetrapeptides structure containing RGD had a definite contribution to the activity.

Acknowledgements

This work was supported by the National Natural Scientific Foundation of China (20642004), the Educational Council Foundation of Beijing (KM200710025012), the National Basic Research Program of China (2011CB504100), the National Natural Scientific Foundation of China (81030062) and Key National Science & Technology Specific Projects (2011ZX09102-003-01). Academic Human Resources Development in Institutions of Higher Learning Under the Jurisdiction of Beijing Municipality (PHR201007114), Beijing Pharmacological Society (2013BI-01).

References

1. Yao N, Fung G, Malekan H, Ye L, Kurth MJ, et al. (2010) Facile synthesis of glycosylated Fmoc amino acid building blocks assisted by microwave irradiation. *Carbohydr Res* 345: 2277-2281.
2. Inaba Y, Kawakami T, Aimoto S, Ikegami T, Takeuchi T, et al. (2009) Preparation and conformational analysis of C-glycosyl beta(2)- and beta/beta(2)-peptides. *Carbohydr Res* 344: 613-626.
3. Dwek RA (1996) Glycobiology: Toward Understanding the Function of Sugars. *Chem Rev* 96: 683-720.
4. Varki A (1993) Biological roles of oligosaccharides: all of the theories are correct. *Glycobiology* 3: 97-130.
5. Wong C (1999) Mimics of complex carbohydrates recognized by receptors. *Chem Res* 32: 376-385.
6. Herzner H, Reipen T, Schultz M, Kunz H (2000) Synthesis of glycopeptides containing carbohydrate and Peptide recognition motifs. *Chem Rev* 100: 4495-4538.
7. Lis H, Sharon N (1993) Protein glycosylation. Structural and functional aspects. *Eur J Biochem* 218: 1-27.
8. Collins BE, Paulson JC (2004) Cell surface biology mediated by low affinity multivalent protein-glycan interactions. *Curr Opin Chem Biol* 8: 617-625.
9. Berger EG, Buddecke E, Kamerling JP, Kobata A, Paulson JC, et al. (1982) Structure, biosynthesis and functions of glycoprotein glycans. *Experientia* 38: 1129-1162.
10. Blithe DL (1993) Biological functions of oligosaccharides on glycoproteins. *Trends Glycosci. Glycotech.* 5: 81-98.
11. Takeuchi M, Takasaki S, Shimada M, Kobata A (1990) Role of sugar chains in the in vitro biological activity of human erythropoietin produced in recombinant Chinese hamster ovary cells. *J Biol Chem* 265: 12127-12130.
12. Takeuchi M, Inoue N, Stickland TW, Kubota M, Wada M, et al. (1989) Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. *USA Proc Natl Acad Sci* 86: 7819-7822.
13. Jennings HJ (1990) Capsular polysaccharides as vaccine candidates. *Curr Top Microbiol Immunol* 150: 97-127.
14. Jennings HJ (1988) Chemically modified capsular polysaccharides as vaccines. *Adv Exp Med Biol* 228: 495-500.
15. Lee CJ (1987) Bacterial capsular polysaccharides—biochemistry, immunity and vaccine. *Mol Immunol* 24: 1005-1019.
16. Weintraub A (2003) Immunology of bacterial polysaccharide antigens. *Carbohydr Res* 338: 2539-2547.
17. Wang LX, Ni J, Singh S, Li H (2004) Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design. *Chem Biol* 11: 127-134.
18. Johnson MA, Pinto BM (2002) Molecular Mimicry of Carbohydrates by Peptides. *Aust J Chem* 55: 13-25.
19. Routenberg LK, Seeberger PH (2004) Automated Solid-Phase Synthesis of Protected Tumor-Associated Antigen and Blood Group Determinant Oligosaccharides. *Angew Chem* 116: 612-615.
20. Plante OJ, Palmacci ER, Seeberger PH (2003) Development of an automated oligosaccharide synthesizer. *Adv Carbohydr Chem Biochem* 58: 35-54.
21. Kelly GS (1998) The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. *Altern Med Rev* 3: 27-39.
22. Xing R, Liu S, Guo Z, Yu H, Li C, et al. (2006) The antioxidant activity of glucosamine hydrochloride in vitro. *Bioorg Med Chem* 14: 1706-1709.
23. Arnaout MA, Goodman SL, Xiong JP (2002) Coming to grips with integrin binding to ligands. *Curr Opin Cell Biol* 14: 641-651.
24. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW (2000) Ligand binding to integrins. *J Biol Chem* 275: 21785-21788.
25. Trabocchi A, Menchi G, Cini N, Bianchini F, Raspanti S, et al. (2010) Click-chemistry-derived triazole ligands of arginine-glycine-aspartate (RGD) integrins with a broad capacity to inhibit adhesion of melanoma cells and both in vitro and in vivo angiogenesis. *J Med Chem* 53: 7119-7128.
26. Varner JA, Cheresh DA (1996) Integrins and cancer. *Curr Opin Cell Biol* 8: 724-730.
27. Yin RT, Zheng H, Xi T, Xu HM (2010) Effect of RGD-4C Position is More Important than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide. *Bioconjugate Chem* 21: 1142-1147.
28. Getlik M, Grutter C, Simard JR, Kluter S, Rabiller M, et al. (2009) Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. *J Med Chem* 52: 3915-3926.
29. Morphy R, Kay C, Rankovic Z (2004) From magic bullets to designed multiple ligands. *Drug Discov Today* 9: 641-651.
30. Natarajan A, Guo Y, Harbinski F, Fan YH, Chen H, et al. (2004) Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation. *J Med Chem* 47: 4979-4982.
31. Romagnoli R, Baraldi PG, Tabrizi MA, Bermejo J, Estevez F, et al. (2005) Design, synthesis, and biological evaluation of hybrid molecules containing alpha-methylene-gamma-butyrolactones and alpha-bromoacryloyl moieties. *J Med Chem* 48: 7906-7910.
32. Baraldi PG, Romagnoli R, Guadix AE, Pineda de las Infantas MJ, Gallo MA, et al. (2002) Design, synthesis, and biological activity of hybrid compounds between uramustine and DNA minor groove binder distamycin A. *J Med Chem* 45: 3630-3638.
33. Watanabe A, Kai T, Nagase H (2006) Novel synthesis of the ortho ester derivative of 4,5-epoxymorphinan. *Org Lett* 8: 523-526.
34. Dal Pozzo A, Ni MH, Esposito E, Dallavalle S, Musso L, et al. (2010) Novel tumor-targeted RGD peptide-camptothecin conjugates: synthesis and biological evaluation. *Bioorg Med Chem* 18: 64-72.
35. Seo J, Michaelian N, Owens SC, Dashner ST, Wong AJ, et al. (2009) Chemoselective and microwave-assisted synthesis of glycopeptoids. *Org Lett* 11: 5210-5213.
36. Zhang J, Zhao M, Peng S (2011) Synthesis of mimetic peptides containing glucosamine. *Carbohydr Res* 346: 1997-2003.
37. Zeng L, Zhang J (2012) Design, synthesis, and evaluation of a novel class of 2,3-disubstituted-tetrahydro- β -carboline derivatives. *Bioorg Med Chem Lett* 22: 3718-3722.
38. Agarwal J, Peddinti RK (2011) Glucosamine-based primary amines as organocatalysts for the asymmetric aldol reaction. *J Org Chem* 76: 3502-3505.
39. Li X, Zhao M, Tang YR, Wang C, Zhang Z, et al. (2008) N-[2-(5,5-dimethyl-3-dioxane-2-yl)ethyl]amino acids: their synthesis, anti-inflammatory evaluation and QSAR analysis. *Eur J Med Chem* 43: 8-18.

Citation: Xu G, Wang X, Zhang M, Zeng L, Li H, et al. (2014) Design, Synthesis, and Evaluation of Glycopeptides Containing Glucosamine. Med chem 4: 494-500. doi:10.4172/2161-0444.1000184